Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 536-539

  Norgard, Nicholas B ^a   Saya, S ^b   Hann, C L ^b   Hennebry, T A ^b   Schechter, E ^b   Dale, G L ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet; Clopidogrel; Coated platelets; Platelets

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CONVULXIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; LECTIN; PURINERGIC P2 RECEPTOR; SNAKE VENOM; THROMBIN; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART CATHETERIZATION; HUMAN; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; THROMBOCYTOPOIESIS; AGED; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; CROTALID VENOMS; FEMALE; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; THROMBIN; TICLOPIDINE;

EID: 59449086953     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181907390     Document Type: Article

References (10)

1. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216-235.
2. Steinhubl SR, Moliterno SSD, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005;5: 399-408.
3. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185-2192.
4. Norgard NB, Hahn CL, Dale GL. Cangrelor attenuates coated-platelet formation. Clin Appl Thromb Hemost. 2008 Sep 15. [Epub ahead of print]. 5. Kotova YN, Ataullakhanov FI, Panteleev MA. Coated platelets formation is regulated by the dense granule secretion of ADP acting via the P2Y12 receptor. J Thromb Haemost. 2008;6:1603-1605.
5. Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95: 1694-1702.
6. Prodan CI, Ross ED, Vincent AS, et al. Coated-platelets are higher in amnestic versus nonamnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord. 2007;21:259-261.
7. Prodan CI, Joseph PM, Vincent AS, et al. Coated-platelets in ischemic stroke: differences between lacunar and cortical stroke. J Thromb Haemost. 2008;6:609-614.
8. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol. 1997;29:13-20.
9. Peltonen S, Lassila R, Heikkilä J. Activation of coagulation and fibrinolysis despite heparinization during successful elective coronary angioplasty. Thromb Res. 1996;82:459-468.
10. Di Nisio M, Bijsterveld N, Meijers J, et al. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndrome. J Am Coll Cardiol. 2005;46: 1582-1583.